PODCAST | Editorial board member John Wilding discusses the lessons for healthcare professionals from the SGLT2 inhibitor cardiovascular outcome trials about the benefits and drawbacks of the medication class.
View more on Medicine Matters diabetes: https://bit.ly/Wilding-SGLT2is-podcast
More podcasts: https://bit.ly/med-mat-podcasts
*Originally published on Medicine Matters diabetes on September 8, 2017*
Video Rating: / 5
